Literature summary for 4.6.1.1 extracted from

Mou, T.C.; Gille, A.; Suryanarayana, S.; Richter, M.; Seifert, R.; Sprang, S.R.
Broad specificity of mammalian adenylyl cyclase for interaction with 2,3-substituted purine- and pyrimidine nucleotide inhibitors (2006), Mol. Pharmacol., 70, 878-886.

Activating Compound

Activating Compound	Comment	Organism
forskolin	catalytic heterodimer VC1-IIC2	Rattus norvegicus
forskolin	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
Galphas	catalytic heterodimer VC1-IIC2	Rattus norvegicus
Galphas	catalytic heterodimer VC1-IIC2	Canis lupus familiaris

Crystallization (Commentary)

Crystallization (Comment)	Organism
crystal structures of catalytic domains VC1-IIC2 bound to 2'(3')-O-(N-methylanthraniloyl)-GTP, 2'(3')-O-(N-methylanthraniloyl)-ATP, and 2',3'-(2,4,6-trinitrophenyl)-ATP, at 2.9 to 3.3 A resolution, inhibitors reside in the same binding pocket in the VC1-IIC2 protein complex, but there are substantial differences in interactions of base, fluorophore, and polyphosphate chain of the inhibitors with mAC	Rattus norvegicus
crystal structures of catalytic domains VC1-IIC2 bound to 2'(3')-O-(N-methylanthraniloyl)-GTP, 2'(3')-O-(N-methylanthraniloyl)-ATP, and 2',3'-(2,4,6-trinitrophenyl)-ATP, at 2.9 to 3.3 A resolution, inhibitors reside in the same binding pocket in the VC1-IIC2 protein complex, but there are substantial differences in interactions of base, fluorophore, and polyphosphate chain of the inhibitors with mAC	Canis lupus familiaris

Crystallization (Comment)

Organism

crystal structures of catalytic domains VC1-IIC2 bound to 2'(3')-O-(N-methylanthraniloyl)-GTP, 2'(3')-O-(N-methylanthraniloyl)-ATP, and 2',3'-(2,4,6-trinitrophenyl)-ATP, at 2.9 to 3.3 A resolution, inhibitors reside in the same binding pocket in the VC1-IIC2 protein complex, but there are substantial differences in interactions of base, fluorophore, and polyphosphate chain of the inhibitors with mAC

Rattus norvegicus

Canis lupus familiaris

Inhibitors

Inhibitors	Comment	Organism
2'(3')-O-(N-methylanthraniloyl)-ATP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2'(3')-O-(N-methylanthraniloyl)-ATP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
2'(3')-O-(N-methylanthraniloyl)-GTP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2'(3')-O-(N-methylanthraniloyl)-GTP	catalytic heterodimer VC1-IIC2, incompletely defined structure 2'- or 3'-substituted nucleoside triphosphate	Rattus norvegicus
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	-	Canis lupus familiaris
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	-	Rattus norvegicus
2',3'-O-(2,4,6-trinitrophenyl)-ADP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-O-(2,4,6-trinitrophenyl)-ADP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
2',3'-O-(2,4,6-trinitrophenyl)-AMP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-O-(2,4,6-trinitrophenyl)-AMP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
2',3'-O-(2,4,6-trinitrophenyl)-ATP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-O-(2,4,6-trinitrophenyl)-ATP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
2',3'-O-(2,4,6-trinitrophenyl)-CTP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-O-(2,4,6-trinitrophenyl)-CTP	catalytic heterodimer VC1-IIC2, incompletely defined structure 2'- or 3'-substituted nucleoside triphosphate	Rattus norvegicus
2',3'-O-(2,4,6-trinitrophenyl)-GDP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-O-(2,4,6-trinitrophenyl)-GDP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
2',3'-O-(2,4,6-trinitrophenyl)-GTP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-O-(2,4,6-trinitrophenyl)-GTP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
2',3'-O-(2,4,6-trinitrophenyl)-UTP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
2',3'-O-(2,4,6-trinitrophenyl)-UTP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP	catalytic heterodimer VC1-IIC2	Rattus norvegicus
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP	catalytic heterodimer VC1-IIC2	Rattus norvegicus

Metals/Ions

Metals/Ions	Comment	Organism	Structure
Mn2+	catalytic heterodimer VC1-IIC2	Rattus norvegicus
Mn2+	catalytic heterodimer VC1-IIC2	Canis lupus familiaris

Organism

Organism	UniProt	Comment	Textmining
Canis lupus familiaris	-	-	-
Rattus norvegicus	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
ATP	catalytic heterodimer VC1-IIC2	Rattus norvegicus	3',5'-cAMP + diphosphate	-	?
ATP	catalytic heterodimer VC1-IIC2	Canis lupus familiaris	3',5'-cAMP + diphosphate	-	?

Synonyms

Synonyms	Comment	Organism
mAC	C1 domain of type V mAC (VC1)	Canis lupus familiaris
mAC	C2 domain of type II mAC (IIC2)	Rattus norvegicus
membrane adenylyl cyclase	-	Rattus norvegicus
membrane adenylyl cyclase	-	Canis lupus familiaris

Ki Value [mM]

Ki Value [mM]	Ki Value maximum [mM]	Inhibitor	Comment	Organism
0.000011	-	2'(3')-O-(N-methylanthraniloyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.000011	-	2'(3')-O-(N-methylanthraniloyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.000014	-	2'(3')-O-(N-methylanthraniloyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.000014	-	2'(3')-O-(N-methylanthraniloyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.000081	-	2',3'-O-(2,4,6-trinitrophenyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.000081	-	2',3'-O-(2,4,6-trinitrophenyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.000083	-	2',3'-O-(2,4,6-trinitrophenyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.000083	-	2',3'-O-(2,4,6-trinitrophenyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.000092	-	2',3'-O-(2,4,6-trinitrophenyl)-UTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.000092	-	2',3'-O-(2,4,6-trinitrophenyl)-UTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.000092	-	2',3'-O-(2,4,6-trinitrophenyl)-UTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.000092	-	2',3'-O-(2,4,6-trinitrophenyl)-UTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.0001	-	2',3'-O-(2,4,6-trinitrophenyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.0001	-	2',3'-O-(2,4,6-trinitrophenyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.00011	-	2'(3')-O-(N-methylanthraniloyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.00011	-	2'(3')-O-(N-methylanthraniloyl)-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.00011	-	2',3'-O-(2,4,6-trinitrophenyl)-CTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.00011	-	2',3'-O-(2,4,6-trinitrophenyl)-CTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.00013	-	2'(3')-O-(N-methylanthraniloyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.00013	-	2'(3')-O-(N-methylanthraniloyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.00031	-	2',3'-O-(2,4,6-trinitrophenyl)-CTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.00031	-	2',3'-O-(2,4,6-trinitrophenyl)-CTP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.00043	-	2',3'-O-(2,4,6-trinitrophenyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.00043	-	2',3'-O-(2,4,6-trinitrophenyl)-GTP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.0013	-	2',3'-O-(2,4,6-trinitrophenyl)-ADP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.0013	-	2',3'-O-(2,4,6-trinitrophenyl)-ADP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.002	-	2',3'-O-(2,4,6-trinitrophenyl)-ADP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.002	-	2',3'-O-(2,4,6-trinitrophenyl)-ADP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.0055	-	2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.0055	-	2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.0067	-	2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.0067	-	2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.0081	-	2',3'-O-(2,4,6-trinitrophenyl)-GDP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.0081	-	2',3'-O-(2,4,6-trinitrophenyl)-GDP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.0094	-	2',3'-O-(2,4,6-trinitrophenyl)-GDP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.0094	-	2',3'-O-(2,4,6-trinitrophenyl)-GDP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.0094	-	N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.0094	-	N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.0094	-	8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.0094	-	8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.01	-	8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.01	-	8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.011	-	N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.011	-	N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.017	-	2',3'-O-(2,4,6-trinitrophenyl)-AMP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.017	-	2',3'-O-(2,4,6-trinitrophenyl)-AMP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris
0.021	-	2',3'-O-(2,4,6-trinitrophenyl)-AMP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.021	-	2',3'-O-(2,4,6-trinitrophenyl)-AMP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.058	-	8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Rattus norvegicus
0.058	-	8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin	Canis lupus familiaris
0.1	-	8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Rattus norvegicus
0.1	-	8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP	VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas	Canis lupus familiaris